Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors

Table 1 Clinicopathological and molecular characteristics of breast cancers analyzed (n = 33) ^a

Case	Histotype^b	T	N	G^c	ER	PR	HER2 status^d	Ki-67^e	p53	Doxo class^f
BR1	IDC	pT1c	N1a	G2	70%	70%	Neg	10%	Wt	Responder
BR2	IDC	pT2	pNx	G2	90%	70%	Neg	15%	R280G	Responder
BR3	IDC	pT3	N1a	G2	80%	Neg	Neg	20%	Wt	Non Responder
BR4	IDC	pT1c	N0	G2	80%	10%	Pos	10%	Wt	Non Responder
BR5	IDC	pT2	N3a	G3	80%	90%	Neg	20%	Wt	Non Responder
BR6	PC	pT2	N2a	G3	90%	5%	Neg	10%	Wt	Responder
BR7	DLC	pT3	N1	G3	90%	5%	Neg	30%	Wt	Responder
BR8	IDC	pT1c	N1a	G3	80%	70%	Neg	25%	Wt	Responder
BR9	IDC	pT1c	N0	G2	90%	70%	Neg	20%	Wt	Responder
BR10	IDC	pT2	Nx	G2	90%	95%	Neg	15%	Wt	Responder
BR11	PC	pT2	N0	G1	95%	95%	Neg	10%	Wt	Responder
BR12	IDC	pT1c	N0	G3	95%	60%	Neg	40%	Wt	Non Responder
BR13	IDC	pT1c	N0	G2	90%	85%	Neg	15%	Wt	Non Responder
BR14	ILC	pT3	N3a	G3	25%	40%	Pos	20%	Wt	Non Responder
BR15	IDC	pT2	N0	G3	95%	20%	Neg	10%	Wt	Responder
BR16	IDC	pT1c	N0	G2	95%	Neg	Neg	5%	Wt	Non Responder
BR17	IDC	pT1c	N0	G2	95%	95%	Neg	20%	Wt	Non Responder
BR18	IDC	pT3	N3	G3	Neg	Neg	Neg	45%	Wt	Responder
BR19	IDC	pT2	N2	G3	90%	60%	Pos	90%	Wt	Non Responder
BR20	IDC	pT2	N3a	G3	90%	2%	Pos	10%	Wt	Responder
BR21	IDC	pT2	Nx	G3	90%	80%	Neg	30%	Wt	Non Responder
BR22	IDC	pT1c	N0	G1	90%	90%	Neg	5%	Wt	Responder
BR23	IDC	pT1c	Nx	G2	90%	40%	Neg	20%	Wt	Responder
BR24	IDC	pT1c	Nx	G2	95%	95%	Neg	5%	Wt	Responder
BR25	IDC	pT2	N2a	G1	90%	75%	Neg	5%	K132N	Responder
BR26	IDC	pT2	N1a	G2	90%	70%	Neg	10%	Wt	Non Responder
BR27	IDC	pT1c	N0	G3	90%	90%	Neg	20%	Wt	Non Responder
BR28	IDC	pT2	N1a	G3	90%	10%	Neg	30%	Wt	Responder
BR29	IDC	pT1c	N0	G3	90%	Neg	Neg	25%	Wt	Responder
BR30	IDC	pT1c	N1a	G1	95%	95%	Neg	5%	Wt	Responder
BR31	IDC	pT1c	N0	G3	Neg	Neg	Neg	40%	Wt	Non Responder
BR32	IDC	pT2	N1a	G3	95%	70%	Neg	25%	R248W	Non Responder
BR33	IDC	pT3	N3a	G2	90%	80%	Neg	10%	Wt	Responder

^aTumor stage according to TNM staging systems, grade, hormone or HER2 receptor status, tumor proliferation (percentage of Ki-67-positive cells), and p53 gene mutations are indicated along with our biological class related to the ex vivo doxorubicin treatment. All patients were M0, that is, no distant metastases were present at diagnosis. ^bIDC, invasive ductal carcinoma; PC, papillary carcinoma; DLC, ductal and lobular carcinoma; ILC, invasive lobular carcinoma.^cG, tumor grade. ^dHER2 status was determined according to American Society of Clinical Oncology guidelines (2007). ^eKi-67 index as determined at diagnosis (approximate to the nearest 5%). ^fDoxorubicin class was assigned to breast cancers depending on the decrease of proliferating cells upon ex vivo doxorubicin treatment of at least 50% (Responders) or the maintenance of Ki-67-positive cells similar to control treated cultures (Non Responders).

ISSN: 1465-542X